Found: 7
Select item for more details and to access through your institution.
Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1302015
- By:
- Publication type:
- Article
Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2023.1295639
- By:
- Publication type:
- Article
Effects of somatostatin receptor type 2 antagonism during insulin‐induced hypoglycaemia in male rats with prediabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1547, doi. 10.1111/dom.15002
- By:
- Publication type:
- Article
Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.
- Published in:
- Endocrinology, 2021, v. 162, n. 12, p. 1, doi. 10.1210/endocr/bqab189
- By:
- Publication type:
- Article
133-OR: Somatostatin Receptor Type 2 Antagonism (SSTR2a) Augments Glucagon Counterregulation and Delays Hypoglycemia Onset in Type 2 Diabetic (T2D), Sprague-Dawley Rats.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-133-OR
- By:
- Publication type:
- Article
1197-P: Effect of Somatostatin Receptor 2 Antagonist (SSTR2a) on Glycemia and Glucagon Levels in a Rat Model of Type 2 Diabetes (T2D).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-1197-P
- By:
- Publication type:
- Article
14-LB: Somatostatin Receptor 2 Antagonism Enhances Plasma Glucagon Levels during Insulin-Induced Hypoglycemia in a Rodent Model of Type 2 Diabetes Mellitus.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-14-LB
- By:
- Publication type:
- Article